Alzheimer's failure spawns 130 job cuts at J&J

A doomed Alzheimer's program has triggered layoffs. Johnson & Johnson ($JNJ) is making deep cuts in an Alzheimer's immunotherapy unit in the aftermath of a colossal Phase III failure of a program to advance bapineuzumab against the memory-stealing disease. Report

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.